By
WilD on
November 26, 2011
Welcome back to our Saturday diabetes advice column, Ask D’Mine, hosted by veteran type 1, diabetes author and community educator Wil Dubois — where myths get busted and unseemly topics sometimes see the light of day. Hey, where else ya gonna turn?
{Need help navigating life with diabetes? Email us at AskDMine@diabetesmine.com}
First things first this week:
Exercising over 250 mg/dL CORRECTION:
Last week we talked about how it’s generally considered unsafe to start…
Read more »
Since we tend to be pretty America-centric over here, we wanted to shine a spotlight on the annual conference for the European Association for the Study of Diabetes (EASD), which is Europe’s equivalent to the American Diabetes Association. EASD is a huge professional org for doctors, researchers, nurses, students, and so on, with 7,000 members — from 110 different countries!
In addition to the annual conference, the EASD also produces their own trade publication, Diabetologia,…
Read more »
Health professionals reportedly are receiving letters this week alerting them to an FDA warning just issued about risks of thyroid cancer and pancreatitis associated with the popular type 2 diabetes drug liraglutide (Victoza). Yikes!
According to MSM reports, the evidence was found in mice, and it’s unclear if the serious risks translate to humans — but there was enough concern to issue the follow warning:
“Clinical trials have shown more cases of pancreatitis with liraglutide…
Read more »
The world of type 2 diabetes drugs is wacky indeed. While Amylin’s long-acting version of Byetta — called Bydureon and predicted by many experts to become a blockbuster — is still held up at FDA, the agency approved a new oral drug earlier this month that is reportedly unremarkable except in the lawsuit it has spurred.
The drug is called linagliptin, brand name Tradjenta, a new oral DPP-4 inhibitor from Eli Lilly and Boehringer that…
Read more »
